BioCatalystWatch
ZYMEWorkspace / ZYME / OverviewCompany library
Price
Market cap
Next catalystDec 13, 2026ZW1953 — preclinical AML research · Data readoutCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Other pipelines

Ziihera® (zanidatamab-hrii)

HER2

ZW191

FRα

PreINDP1P2P3FilingApproved
ZW191

FRα

PreINDP1P2P3FilingApproved
ZW251

GPC3

PreINDP1P2P3FilingApproved
ZW209

DLL3 × CD3 × CD28

PreINDP1P2P3FilingApproved
Upcoming / outlook

ZW1528

IL-4Rα × IL-33

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PD-1 × VEGF

ZW1953

FLT3 × CLEC12A × CD33 × CD28

Upcoming / outlook

ZW1572

IL-4Rα × IL-31

PreINDP1P2P3FilingApproved
ZW439

CLDN18.2

PreINDP1P2P3FilingApproved
ZW427

Ly6E

PreINDP1P2P3FilingApproved

Partner / License out

KLK2 × CD3

PreINDP1P2P3FilingApproved

KLK2 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

KLK2 × CD3

PreINDP1P2P3FilingApproved

KLK2 × CD3

PreINDP1P2P3FilingApproved

HLA-G × CD3

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Approved / commercial

HER2

PreINDP1P2P3FilingApproved

Muscarinic receptors

Approved

PreINDP1P2P3FilingApproved

History / paused

NaPi2b

PreINDP2P3FilingApproved

NaPi2b

PreINDP2P3FilingApproved

MSLN × CD3

PreINDP1P2P3FilingApproved

HER2

PreINDP1P2P3FilingApproved

HER2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ZYME PR & News

ZYME SEC archive